Intracellular bacteria recognition contributes to maximal interleukin (IL)-12 production by IL-10-deficient macrophages

Por Naruse, H, Hisamatsu, T, Yamauchi, Y, Chang, J E, Matsuoka, K, Kitazume, M T, Arai, K, Ando, S, Kanai, T, Kamada, N, Hibi, T
Publicado em 2011

Capecitabine and oxaliplatin in combination as first or second-line therapy for metastatic breast cancer: A Wisconsin Oncology Network trial

Por Njiaju, U.O., Tevaarwerk, A.J., Kim, K., Chang, J.E., Hansen, R.M., Champeny, T.L., Traynor, A.M., Meadows, S., Van Ummersen, L., Powers, K., Stewart, J.A.
Publicado em 2012

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

Por Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N.S., Longo, W.L., Kahl, B.S.
Publicado no Clin Lymphoma Myeloma Leuk (2017)

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

Por Chang, J. E., Peterson, C., Choi, S., Eickhoff, J. C., Kim, K., Yang, D. T., Gilbert, L. A., Rogers, E. S., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N. S., Longo, W. L., Kahl, B. S.
Publicado em 2011